These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1059 related articles for article (PubMed ID: 29118007)

  • 41. PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia.
    McClanahan F; Hanna B; Miller S; Clear AJ; Lichter P; Gribben JG; Seiffert M
    Blood; 2015 Jul; 126(2):203-11. PubMed ID: 25800048
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinicopathological Study of PD-1/PD-L1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with Emphasis on Large B-Cell Richter Transformation.
    Masoud R; Eladl AE; El-Ashwah S; Abbas A; Kandil W
    Asian Pac J Cancer Prev; 2023 Dec; 24(12):4243-4252. PubMed ID: 38156860
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
    BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.
    Sznol M; Chen L
    Clin Cancer Res; 2013 Mar; 19(5):1021-34. PubMed ID: 23460533
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nivolumab in the Treatment of Hodgkin Lymphoma.
    Ansell SM
    Clin Cancer Res; 2017 Apr; 23(7):1623-1626. PubMed ID: 27881581
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.
    Šmahel M
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635644
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series.
    Ugurel S; Spassova I; Wohlfarth J; Drusio C; Cherouny A; Melior A; Sucker A; Zimmer L; Ritter C; Schadendorf D; Becker JC
    Cancer Immunol Immunother; 2019 Jun; 68(6):983-990. PubMed ID: 30993371
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.
    van Dam LS; de Zwart VM; Meyer-Wentrup FA
    Pediatr Blood Cancer; 2015 Feb; 62(2):190-197. PubMed ID: 25327979
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
    Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunotherapy of Hodgkin Lymphoma: Mobilizing the Patient's Immune Response.
    Ansell SM
    Cancer J; 2018; 24(5):249-253. PubMed ID: 30247261
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
    Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
    Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
    Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
    Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Saâda-Bouzid E; Defaucheux C; Karabajakian A; Coloma VP; Servois V; Paoletti X; Even C; Fayette J; Guigay J; Loirat D; Peyrade F; Alt M; Gal J; Le Tourneau C
    Ann Oncol; 2017 Jul; 28(7):1605-1611. PubMed ID: 28419181
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.
    Nie J; Wang C; Liu Y; Yang Q; Mei Q; Dong L; Li X; Liu J; Ku W; Zhang Y; Chen M; An X; Shi L; Brock MV; Bai J; Han W
    J Clin Oncol; 2019 Jun; 37(17):1479-1489. PubMed ID: 31039052
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma.
    Kearl TJ; Jing W; Gershan JA; Johnson BD
    J Immunol; 2013 Jun; 190(11):5620-8. PubMed ID: 23616570
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.
    Hamanishi J; Mandai M; Matsumura N; Abiko K; Baba T; Konishi I
    Int J Clin Oncol; 2016 Jun; 21(3):462-73. PubMed ID: 26899259
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The immune landscape and response to immune checkpoint blockade therapy in lymphoma.
    Kline J; Godfrey J; Ansell SM
    Blood; 2020 Feb; 135(8):523-533. PubMed ID: 31790142
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1.
    Bertucci F; Gonçalves A
    Curr Oncol Rep; 2017 Aug; 19(10):64. PubMed ID: 28799073
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade.
    Hirsch L; Zitvogel L; Eggermont A; Marabelle A
    Br J Cancer; 2019 Jan; 120(1):3-5. PubMed ID: 30413824
    [TBL] [Abstract][Full Text] [Related]  

  • 60. TIGIT is Frequently Expressed in the Tumor Microenvironment of Select Lymphomas: Implications for Targeted Therapy.
    Libert D; Zhao S; Younes S; Mosquera AP; Bharadwaj S; Ferreira C; Natkunam Y
    Am J Surg Pathol; 2024 Mar; 48(3):337-352. PubMed ID: 38148663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.